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Background
Bulbine natalensis is a perennial herb indigenous to
South Africa that is currently being marketed as a pro-
sexual product for men. As the first step in a series of
experiments designed to assess in the in vivo effects of
Bulbine natalensis (ProLensis™) supplementation, we
performed a placebo-controlled, double-blind clinical
trial to assess the short-term safety of this ingredient.
Methods
After giving informed consent and being cleared for par-
ticipation by passing a screening physical and EKG, 36
apparently healthy men (mean ± SD age, height, weight:
29.4 ± 7.7 y, 177.2 ± 5.2 cm, 82.2 ± 10.7 kg) consumed 4
capsules of ProLensis™ (325 mg in the morning, 325 mg
six hours later) or a matched placebo every day for 28
days. Clinical chemistry panels (renal, hepatic, and hema-
tological biomarkers) and general markers of health
(heart rate, blood pressure, EKG) were assessed before
and after 28 days of supplementation. Data were analyzed
via ANCOVA using baseline values as the covariate and
statistical significance was set a priori at P≤0.05.
Results
In 27 of 29 variables, no differences were noted between
groups. Alkaline phosphatase (AP) increased marginally
in the ProLensis™group (+2.0 IU/L, +3%) compared to
a parallel decrease the Placebo group (-2.4 IU/L, -3.8%);
P<0.04. In contrast, creatinine (Creat) decreased slightly
in the ProLensis™group (-0.08, -7.4%) compared to no
change in the Placebo group (P<0.003). It is our opinion
that the observed differences in AP and Creat are not
clinically relevant given that all values for both groups
fell well within normative clinical limits (i.e. typical
values for AP range from 20 to 140 IU/L1; typical values
for Creat range from 0.6 to 1.3 mg/dL for men and 0.5
to 1.1 mg/dL for women2).
Conclusions
Within the confines of the current experimental design
(i.e. subject demographics, dose and duration of use)
these preliminary data suggest that ProLensis™is as safe
as Placebo with respect to the hemodynamic, hepatic,
renal, and hematologic biomarkers assessed. Future stu-
dies should seek to clarify extraction methods and bioac-
tive(s), investigate potential efficacy, and confirm these
safety data to strengthen the total body of evidence.
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